Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Cost of Revenue

Last Annual Value

7.32M

3-Year CAGR

%

5-Year CAGR

20%

10-Year CAGR

10%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Cost of Revenue

PRME · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
7.32M
N/AN/AN/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
5.72M
N/AN/AN/A
57.00K
-59.4%N/A6.3%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
0.00
N/AN/AN/A
2.07M
-23.6%-24.1%9.7%
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
152.35M
0.8%1.6%N/A
546.00K
N/AN/AN/A
11.71M
-72.7%-53.1%N/A
0.00
N/AN/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14